Acute hypertriglyceridemia promotes intestinal lymphatic lipid and drug transport: A positive feedback mechanism in lipid and drug absorption

Molecular Pharmaceutics

Volumn 8, Issue 4, 2011, Pages 1132-1139

  Trevaskis, Natalie L ^a   Charman, William N ^a   Porter, Christopher J H ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

atherosclerosis; drug absorption; dyslipidemia; hypertriglyceridemia; lipid absorption; lipoprotein; lymphatic drug transport; metabolic disease; triglyceride rich lipoprotein

Indexed keywords

CARBON 14; CHYLOMICRON; FATTY ACID; HALOFANTRINE; LIPOPROTEIN; OLEIC ACID; TRIGLYCERIDE RICH LIPOPROTEIN; UNCLASSIFIED DRUG;

ACUTE DISEASE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BILE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG TRANSPORT; FATTY ACID BLOOD LEVEL; HYPERTRIGLYCERIDEMIA; INTESTINE LYMPH; LIPID ABSORPTION; LIPID TRANSPORT; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; BIOLOGICAL TRANSPORT; CHYLOMICRONS; FATTY ACIDS; HYPERTRIGLYCERIDEMIA; INTESTINES; LIPOPROTEINS; MALE; MODELS, BIOLOGICAL; OLEIC ACID; PHENANTHRENES; RATS; RATS, SPRAGUE-DAWLEY; TRIGLYCERIDES;

EID: 79961069495     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp100462d     Document Type: Article

References (35)

1. Mediene-Benchekor, S.; Brousseau, T.; Richard, F.; Benhamamouch, S.; Amouyel, P. Blood lipid concentrations and risk of myocardial infarction Lancet 2001, 358, 1064-1065 (Pubitemid 32925131)
2. Cabezas, M. C.; Erkelens, D. W. Triglycerides and atherosclerosis: to feast or fast Neth. J. Med. 2000, 56, 110-118 (Pubitemid 30089028)
3. Proctor, S. D.; Vine, D. F.; Mamo, J. C. Arterial retention of apolipoprotein B(48)- and B(100)-containing lipoproteins in atherogenesis Curr. Opin. Lipidol. 2002, 13, 461-470 (Pubitemid 35231925)
4. Zilversmit, D. B. Atherogenic nature of triglycerides, postprandial lipidemia, and triglyceride-rich remnant lipoproteins Clin. Chem. 1995, 41, 153-158
5. Duez, H.; Pavlic, M.; Lewis, G. F. Mechanism of intestinal lipoprotein overproduction in insulin resistant humans Atheroscler. Suppl. 2008, 9, 33-38
6. Vine, D. F.; Glimm, D. R.; Proctor, S. D. Intestinal lipid transport and chylomicron production: possible links to exacerbated atherogenesis in a rodent model of the metabolic syndrome Atheroscler. Suppl. 2008, 9, 69-76
7. Duez, H. Both intestinal and hepatic lipoprotein production are stimulated by an acute elevation of plasma free fatty acids in humans Circulation 2008, 117, 2369-2376 (Pubitemid 351653555)
8. Lewis, G. F. Intestinal lipoprotein production is stimulated by an acute elevation of plasma free fatty acids in the fasting state: studies in insulin-resistant and insulin-sensitized Syrian golden hamsters Endocrinology 2004, 145, 5006-5012 (Pubitemid 39551119)
9. Guo, Q.; Avramoglu, R. K.; Adeli, K. Intestinal assembly and secretion of highly dense/lipid-poor apolipoprotein B48-containing lipoprotein particles in the fasting state: evidence for induction by insulin resistance and exogenous fatty acids Metabolism 2005, 54, 689-697 (Pubitemid 40585660)
10. Sasase, T. Increased fat absorption and impaired fat clearance cause postprandial hypertriglyceridemia in Spontaneously Diabetic Torii rat Diabetes Res. Clin. Pract. 2007, 78, 8-15 (Pubitemid 47348156)
11. Zoltowska, M. Cellular aspects of intestinal lipoprotein assembly in Psammomys obesus: a model of insulin resistance and type 2 diabetes Diabetes 2003, 52, 2539-2545 (Pubitemid 37210543)
12. Popper, D. A.; Shiau, Y. F.; Reed, M. Role of small intestine in pathogenesis of hyperlipidemia in diabetic rats Am. J. Physiol. 1985, 249, G161-167
13. Hsieh, J.; Hayashi, A. A.; Webb, J.; Adeli, K. Postprandial dyslipidemia in insulin resistance: mechanisms and role of intestinal insulin sensitivity Atheroscler. Suppl. 2008, 9, 7-13
14. Pavlic, M.; Xiao, C.; Szeto, L.; Patterson, B. W.; Lewis, G. F. Insulin acutely inhibits intestinal lipoprotein secretion in humans in part by suppressing plasma free fatty acids Diabetes 2010, 59, 580-587
15. Wasan, K. M.; Brocks, D. R.; Lee, S. D.; Sachs-Barrable, K.; Thornton, S. J. Impact of lipoproteins on the biological activity and disposition of hydrophobic drugs: implications for drug discovery Nat. Rev. Drug Discovery 2008, 7, 84-99
16. Humberstone, A. J.; Porter, C. J. H.; Edwards, G. A.; Charman, W. N. Association of halofantrine with postprandially derived plasma lipoproteins decreases its clearance relative to administration in the fasted state J. Pharm. Sci. 1998, 87, 936-942 (Pubitemid 28381250)
17. Porter, C. J. H.; Trevaskis, N. L.; Charman, W. N. Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs Nat. Rev. Drug Discovery 2007, 6, 231-248 (Pubitemid 46344627)
18. Trevaskis, N. L.; Charman, W. N.; Porter, C. J. H. Lipid-based delivery systems and intestinal lymphatic drug transport: a mechanistic update Adv. Drug Delivery Rev. 2008, 60, 702-716
19. Johnson, B. M.; Chen, W.; Borchardt, R. T.; Charman, W. N.; Porter, C. J. H. A kinetic evaluation of the absorption, efflux, and metabolism of verapamil in the autoperfused rat jejunum J. Pharmacol. Exp. Ther. 2003, 305, 151-158 (Pubitemid 36373845)
20. Trevaskis, N. L.; Porter, C. J. H.; Charman, W. N. Bile increases intestinal lymphatic drug transport in the fasted rat Pharm. Res. 2005, 22, 1863-1870 (Pubitemid 41504339)
21. Trevaskis, N. L.; Porter, C. J. H.; Charman, W. N. The lymph lipid precursor pool is a key determinant of intestinal lymphatic drug transport J. Pharmacol. Exp. Ther. 2006, 316, 881-891 (Pubitemid 43131018)
22. Charman, W. N.; Stella, V. J. Lymphatic transport of drugs; CRC Press: Boca Raton, 1992.
23. Humberstone, A. J.; Currie, G. J.; Porter, C. J. H.; Scanlon, M. J.; Charman, W. N. A simplified liquid chromatography assay for the quantitation of halofantrine and desbutylhalofantrine in plasma and identification of a degradation product of desbutylhalofantrine formed under alkaline conditions J. Pharm. Biomed. Anal. 1995, 13, 265-272
24. Smit, M. J.; Temmerman, A. M.; Havinga, R.; Kuipers, F.; Vonk, R. J. Short- and long-term effects of biliary drainage on hepatic cholesterol metabolism in the rat Biochem. J. 1990, 269, 781-788 (Pubitemid 20236091)
25. Duez, H. Hyperinsulinemia is associated with increased production rate of intestinal apolipoprotein B-48-containing lipoproteins in humans Arterioscler. Thromb. Vasc. Biol. 2006, 26, 1357-1363 (Pubitemid 44305382)
26. Shiau, Y. F. Intestinal triglycerides are derived from both endogenous and exogenous sources Am. J. Physiol. 1985, 248, G164-169
27. Anzai, K. Increased lipid absorption and transport in the small intestine of zucker obese rats J. Clin. Biochem. Nutr. 2009, 45, 82-85
28. Saltiel, A. R.; Kahn, C. R. Insulin signalling and the regulation of glucose and lipid metabolism Nature 2001, 414, 799-806 (Pubitemid 34000783)
29. Chabowski, A. Insulin stimulates fatty acid transport by regulating expression of FAT/CD36 but not FABPpm Am. J. Physiol. 2004, 287, E781-789
30. Hsieh, J. Glucagon-like peptide-2 increases intestinal lipid absorption and chylomicron production via CD36 Gastroenterology 2009, 137, 997-1005
31. Charman, W. N.; Stella, V. J. Effect of lipid class and lipid vehicle volume on the intestinal lymphatic transport of DDT Int. J. Pharm. 1986, 33, 165-172 (Pubitemid 17197800)
32. White, K. L. Lymphatic transport of Methylnortestosterone undecanoate (MU) and the bioavailability of methylnortestosterone are highly sensitive to the mass of coadministered lipid after oral administration of MU J. Pharmacol. Exp. Ther. 2009, 331, 700-709
33. Trevaskis, N. L.; Shanker, R. M.; Charman, W. N.; Porter, C. J. H. The Mechanism of Lymphatic Access of Two Cholesteryl Ester Transfer Protein Inhibitors (CP524,515 and CP532,623) and Evaluation of Their Impact on Lymph Lipoprotein Profiles Pharm. Res. 2010, 27, 1949-1964
34. Trevaskis, N. L. Intestinal lymphatic transport enhances the post-prandial oral bioavailability of a novel cannabinoid receptor agonist via avoidance of first-pass metabolism Pharm. Res. 2009, 26, 1486-1495
35. Khoo, S. M.; Edwards, G. A.; Porter, C. J. H.; Charman, W. N. A conscious dog model for assessing the absorption, enterocyte-based metabolism, and intestinal lymphatic transport of halofantrine J. Pharm. Sci. 2001, 90, 1599-1607 (Pubitemid 32979754)